5 Year Veterans Administration Contract Extension

AOTI, INC., a medical technology group focused on the durable healing of wounds and prevention of amputations, is pleased to announce that it has been awarded another five-year extension to its Federal Supply Schedule (FSS) contract for its Topical Wound Oxygen (TWO2®) therapy and NEXA NPWT products by the U.S. Department of Veterans Affairs (VA).

The Veterans Health Administration is America's largest integrated health care system, providing care at 1,380 health care facilities, including 170 medical centers and 1,193 outpatient sites of care, serving 9.1 million enrolled veterans each year.

The VA FSS programme supports the healthcare requirements of the VA and other federal Government agencies by negotiating contracts with pre-approved vendors for fixed most favoured customer pricing, providing them access to medical equipment, supplies, pharmaceutical, and service programmes that totalled over $18.9 billion during fiscal year 2023.

The Company's FSS contract is now active through to 14 June 2029, enabling AOTI to continue to provide its multi-modality TWO2® therapy and NEXA NPWT products to clinicians and veterans within the VA and other federal healthcare programmes. The Company was first awarded an FSS contract in 2009 and has since treated thousands of veterans across the US, with its unique TWO2® therapy, which is differentiated from all other wound treatment modalities by its clinically proven ability to more durably heal wounds, save limbs and reduce costs.

Dr. Mike Griffiths, Chief Executive Officer and President of AOTI, INC., commented: "We have proudly served the veteran community for over 15 years. We are delighted to be awarded a new five-year extension to our contract which has consistent pricing and some improved terms, allowing us to continue to strengthen our effective partnership. Promoting health equity and addressing outcome disparities in patients with non-healing wounds is central to our mission at AOTI. Our unique TWO2® therapy has revolutionised chronic wound healing by providing significant reductions in wound related reoccurrence, hospitalisations and amputations1,2. With TWO2® therapy being primarily applied by veterans at home, we are driving meaningful improvements in access-to-care for those who need it most."

• Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers; The TWO2 Study. Robert G. Frykberg et al, Diabetics Care 2020; 43:616-624. https://doi.org/10.2337/dc19-0476.
• Reduced Hospitalizations and Amputations in Patients with Diabetic Foot Ulcers Treated with Cyclical Pressurized Topical Wound Oxygen Therapy: Real-World Outcomes; Jessica Izhakoff Yellin, et al; Advances in Wound Care 2022; http://doi.org/10.1089/wound.2021.0118

ABOUT AOTI, INC.